Cynapsus Therapeutics, Inc. (NASDAQ: CYNA)  is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand turning ON of debilitating OFF episodes associated with Parkinson’s disease (PD). The company’s … Continue reading →

Cymabay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. CymaBay was seeded with … Continue reading →

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field … Continue reading →

Critical Outcome Technologies, Inc. (OTC: COTQF) is engaged in disease-specific drug discovery, optimization and pre-clinical development using a specially developed series of computer models. COTI is focused on the discovery and pre-clinical development of small molecules for the treatment of … Continue reading →

Cortex Pharmaceuticals, Inc. (OTC: CORX) has multiple drug development programs targeted toward the treatment of brain-related breathing disorders, such as obstructive or central sleep apnea and drug-induced respiratory depression. One key program involves the development of positive allosteric modulators of … Continue reading →

CorMedix, Inc. (NYSE: CRMD) is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin, a catheter lock … Continue reading →

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) operates as a biopharmaceutical company focused on developing targeted antiviral therapies. The company has two drug candidates in clinical studies. The first, FV-100, is now in phase III trials and being developed for the treatment … Continue reading →

CombiMatrix Corp. (NASDAQ: CBMX) is a clinical diagnostic laboratory specializing in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix offers chromosomal microarray analysis, standard and customized FISH, and high … Continue reading →

Founded in 2005, biopharmaceutical company CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) is focused on developing small molecules for the acute treatment of migraine headaches. The company’s lead product candidates are oral lasmiditan, an oral tablet for the acute treatment of migraine … Continue reading →

Codexis, Inc. (NASDAQ: CDXS) provides unique, state-of-the-art enzyme optimization services and developing biocatalyst products. The company’s technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients (APIs), fine chemicals, agrochemicals, food ingredients, detergents and biofuels. They also enable rapid … Continue reading →